001052252 001__ 1052252
001052252 005__ 20260122203308.0
001052252 0247_ $$2doi$$a10.1093/neuonc/noaf009
001052252 0247_ $$2ISSN$$a1522-8517
001052252 0247_ $$2ISSN$$a1523-5866
001052252 0247_ $$2datacite_doi$$a10.34734/FZJ-2026-00869
001052252 037__ $$aFZJ-2026-00869
001052252 082__ $$a610
001052252 1001_ $$0P:(DE-HGF)0$$aKotecha, Rupesh$$b0$$eCorresponding author
001052252 245__ $$aBenchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design
001052252 260__ $$aOxford$$bOxford Univ. Press$$c2025
001052252 3367_ $$2DRIVER$$aarticle
001052252 3367_ $$2DataCite$$aOutput Types/Journal article
001052252 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769088395_20964
001052252 3367_ $$2BibTeX$$aARTICLE
001052252 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001052252 3367_ $$00$$2EndNote$$aJournal Article
001052252 500__ $$aNeuro Oncol . 2025 Sep 8;27(7):1670-1685.Funding: none declared
001052252 520__ $$aBackground. Despite advances in our understanding of the molecular underpinnings of meningioma progressionand innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge.The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporaryanalysis, and propose a “rate of probable interest” to inform future clinical trial design and development on behalfof the Response Assessment in Neuro-Oncology meningioma group.Methods. PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating theactivity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique withI2 indices.Results. The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI:22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0%(95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%)and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapywere 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors.Conclusions. Several studies have reported outcomes in patients with recurrent meningiomas testing a variety ofagents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarksfor future trials to define efficacy of future investigational therapies.
001052252 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001052252 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001052252 7001_ $$00000-0002-6848-4289$$aAkdemir, Eyub Y$$b1
001052252 7001_ $$0P:(DE-HGF)0$$aKutuk, Tugce$$b2
001052252 7001_ $$0P:(DE-HGF)0$$aIlgın, Can$$b3
001052252 7001_ $$0P:(DE-HGF)0$$aAhluwalia, Manmeet S$$b4
001052252 7001_ $$0P:(DE-HGF)0$$aBi, Wenya L$$b5
001052252 7001_ $$00000-0002-1049-0993$$aBlakeley, Jaishri$$b6
001052252 7001_ $$0P:(DE-HGF)0$$aDixit, Karan S$$b7
001052252 7001_ $$0P:(DE-HGF)0$$aDunn, Ian F$$b8
001052252 7001_ $$00000-0001-8014-786X$$aGalanis, Evanthia$$b9
001052252 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b10
001052252 7001_ $$0P:(DE-HGF)0$$aHuang, Raymond Y$$b11
001052252 7001_ $$0P:(DE-HGF)0$$aJohnson, Derek R$$b12
001052252 7001_ $$0P:(DE-HGF)0$$aKaley, Thomas J$$b13
001052252 7001_ $$0P:(DE-HGF)0$$aKamson, David O$$b14
001052252 7001_ $$0P:(DE-HGF)0$$aKurz, Sylvia C$$b15
001052252 7001_ $$0P:(DE-HGF)0$$aMcDermott, Michael W$$b16
001052252 7001_ $$0P:(DE-HGF)0$$aOdia, Yazmin$$b17
001052252 7001_ $$0P:(DE-HGF)0$$aPreusser, Matthias$$b18
001052252 7001_ $$0P:(DE-HGF)0$$aRaizer, Jeffrey$$b19
001052252 7001_ $$0P:(DE-HGF)0$$aReardon, David A$$b20
001052252 7001_ $$0P:(DE-HGF)0$$aRogers, C Leland$$b21
001052252 7001_ $$0P:(DE-HGF)0$$aRuda, Roberta$$b22
001052252 7001_ $$0P:(DE-HGF)0$$aSchiff, David$$b23
001052252 7001_ $$0P:(DE-HGF)0$$aVogelbaum, Michael A$$b24
001052252 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b25
001052252 7001_ $$00000-0002-0774-7700$$aWen, Patrick Y$$b26
001052252 7001_ $$0P:(DE-HGF)0$$aMehta, Minesh P$$b27
001052252 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noaf009$$gVol. 27, no. 7, p. 1670 - 1685$$n7$$p1670 - 1685$$tNeuro-Oncology$$v27$$x1522-8517$$y2025
001052252 8564_ $$uhttps://juser.fz-juelich.de/record/1052252/files/noaf009.pdf$$yOpenAccess
001052252 909CO $$ooai:juser.fz-juelich.de:1052252$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
001052252 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b10$$kFZJ
001052252 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001052252 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001052252 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
001052252 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
001052252 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
001052252 920__ $$lyes
001052252 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001052252 980__ $$ajournal
001052252 980__ $$aVDB
001052252 980__ $$aUNRESTRICTED
001052252 980__ $$aI:(DE-Juel1)INM-3-20090406
001052252 9801_ $$aFullTexts